Woodline Partners LP Lowers Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Woodline Partners LP trimmed its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 49.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 409,314 shares of the company's stock after selling 406,938 shares during the quarter. Woodline Partners LP owned approximately 0.45% of Aquestive Therapeutics worth $1,457,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. New York State Common Retirement Fund boosted its holdings in Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after purchasing an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Aquestive Therapeutics during the fourth quarter worth about $44,000. Two Sigma Advisers LP bought a new position in Aquestive Therapeutics in the fourth quarter worth about $57,000. PKS Advisory Services LLC acquired a new position in Aquestive Therapeutics during the 4th quarter valued at approximately $63,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Aquestive Therapeutics during the fourth quarter valued at $69,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded up $0.05 during mid-day trading on Thursday, hitting $2.78. The company's stock had a trading volume of 580,930 shares, compared to its average volume of 1,515,774. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80. The company has a market cap of $275.64 million, a PE ratio of -6.17 and a beta of 2.02. The firm's 50 day moving average is $2.68 and its 200 day moving average is $3.22.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The firm had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. As a group, analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Alliance Global Partners restated a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. Finally, Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Friday, March 7th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.